Latest Administration News

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

ENRG Elements Limited has confirmed the materiality of recent director resignations and appointments, clarifying timing and compliance with ASX disclosure rules.

Mosaic Brands’ administrators have adjourned the second creditors’ meeting after no restructuring proposal was submitted, prolonging uncertainty over the retail group’s future.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

Lumos Diagnostics has enrolled 500 patients in its FebriDx CLIA waiver clinical study, unlocking a significant milestone payment from BARDA and moving closer to FDA approval that could open a US$1 billion market.

Makilala Mining has appointed leading consultants to refine and optimise the MCB Copper-Gold Project’s mine plan and infrastructure design, aiming to enhance operational efficiency and environmental outcomes.

Wrkr Ltd has completed a pivotal pilot of its employer services platform with Rest and MUFG Retirement Services, setting the stage for streamlined Payday Super implementation ahead of the July 2026 deadline.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Lotus Resources has begun cold commissioning at its Kayelekera uranium project, targeting a Q3 2025 production restart while adopting an owner-operator mining model to reduce costs and enhance control.